Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Thromb Res. 2016 Jan 5;139:29–37. doi: 10.1016/j.thromres.2016.01.002

Table 3a. Univariate Analysis for Association between Venous Thromboembolism in Cancer Patients and Cancer Site, and After Adjusting for Cancer Site VTE Risk Score, Individual Cancer Sites, and Cancer Stage.

Cancer Site and Stage OR 95% CI* p-value*
Model 1 Two-fold increase in cancer site VTE risk score 1.42 1.22 1.66 <.001
Model 2 Two-fold increase in cancer site score 1.52 1.28 1.82 <.001
Low grade lymphoma 0.34 0.17 0.68 0.002
Medium or high grade lymphoma 1.40 0.62 3.18 0.42
Myeloproliferative neoplasm 18.26 2.40 139.08 0.005
Model 3 Two-fold increase in cancer site VTE risk score 1.44 1.20 1.73 <.001
Low grade lymphoma 0.30 0.15 0.61 <.001
Medium or high grade lymphoma 1.65 0.72 3.78 0.24
Myeloproliferative neoplasm 23.96 3.05 188.00 0.002
Stage 3, 4 vs stage 1, 2 2.00 1.55 2.59 <.001
Model 4 Two-fold increase in cancer site VTE risk score 1.50 1.25 1.81 <.001
Low grade lymphoma 0.30 0.15 0.63 0.001
Medium or high grade lymphoma 1.38 0.63 3.03 0.42
Myeloproliferative neoplasm 28.64 3.53 232.17 0.002
Stage 2, 3, 4 vs stage 1 2.38 1.80 3.16 <.001
*

95% Confidence intervals are calculated using the robust sandwich estimate of Lin and Wei [54] for the covariance and standard error. P-values are Wald p-values from the conditional logistic model using the robust sandwich estimate. Covariates that reached the statistical significance level p≤0.1 are included in this table.